title: Accelerated (9-mW/cm2) corneal collagen crosslinking for keratoconus-A 1-year follow-up.
abstract: OBJECTIVE
  The aim of this study was to assess the efficacy of accelerated crosslinking (irradiance of 9 mW/cm; 10 minutes) in keratoconus-affected eyes through topographical, visual, and refractive end points.
  
  
  METHODS
  Mild-moderate keratoconus-affected eyes that underwent accelerated corneal collagen crosslinking (CXL) treatment and had 6 and 12 months of follow-up were reviewed retrospectively. Data regarding uncorrected distance visual acuity (UDVA), manifest refraction, corrected distance visual acuity (CDVA), and computerized corneal topography data before surgery and post-CXL treatment were extracted and analyzed.
  
  
  RESULTS
  Sixteen eyes of 14 patients were included in the study. The mean patient age was 24.9 ± 5.8 years (range: 17.1-38.3 years). No statistically significant changes were found in the mean CDVA, mean refractive cylinder, or mean manifest refraction spherical equivalent at either time point. There was a gain of 0.13 logarithm of the minimum angle of resolution lines in the mean UDVA (P = 0.012) at 12 months. All corneal parameters including Ksteep, Kflat, average K (Km), corneal astigmatism (Kcyl), and maximal curvature reading at the corneal apex (Kmax) were stable at 6 and 12 months in all patients. No complications were observed during the follow-up period.
  
  
  CONCLUSIONS
  Accelerated corneal CXL is effective in stabilizing topographic parameters after 12 months of follow-up in mild-moderate keratoconus-affected corneas. Improvement in the UDVA and stabilization of all tested corneal parameters were noted after the treatment. However, a longer follow-up with larger cohorts is necessary to validate these findings.
authors.affiliation: Department of Ophthalmology, Toronto Western Hospital, University of Toronto, Yonge Eglinton Laser Eye Center, Toronto, Canada.
authors.forename: Uri
authors.initials: U
authors.lastname: Elbaz
authors.forename: Carl
authors.initials: C
authors.lastname: Shen
authors.forename: Alejandro
authors.initials: A
authors.lastname: Lichtinger
authors.forename: Noa A
authors.initials: NA
authors.lastname: Zauberman
authors.forename: Yakov
authors.initials: Y
authors.lastname: Goldich
authors.forename: Clara C
authors.initials: CC
authors.lastname: Chan
authors.forename: Allan R
authors.initials: AR
authors.lastname: Slomovic
authors.forename: David S
authors.initials: DS
authors.lastname: Rootman
mesh_terms: D000293:Adolescent; D000328:Adult; D003094:Collagen / Q000378:metabolism*; D003319:Corneal Stroma / Q000378:metabolism*; D019781:Corneal Topography; D003432:Cross-Linking Reagents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007640:Keratoconus / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012029:Refraction, Ocular / Q000502:physiology; D012189:Retrospective Studies; D012256:Riboflavin / Q000627:therapeutic use*; D014466:Ultraviolet Rays; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin